Biotest AG (Biotest AG) Float Percentage Of Total Shares Outstanding : 0.00% (As of Jun. 08, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Biotest AG Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Biotest AG's float shares is 0.00 Mil. Biotest AG's total shares outstanding is 39.57 Mil. Biotest AG's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Biotest AG's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Biotest AG's Institutional Ownership is 0.38%.

Biotest AG Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Biotest AG's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	0.00	/	39.57
	=	0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotest AG (Biotest AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotest AG (OTCPK:BIESF) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

BIO3:Germany BIO3:Austria

Address

Landsteinerstrasse 5, Dreieich, DEU, 63303

Website

https://www.biotest.com

Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The operating business segments are Therapy, Plasma and Services, and Other segments. It generates maximum revenue from the Therapy segment. Geographically, it derives a majority of revenue from Central Europe and also has a presence in other countries.